Shares of Ritter Pharmaceuticals, Inc. (NASDAQ:RTTR) have been given a consensus rating of “Buy” by the six ratings firms that are presently covering the stock, Marketbeat reports. One analyst has rated the stock with a hold rating and five have issued a buy rating on the company. The average 1-year target price among brokers that have updated their coverage on the stock in the last year is $4.31.

Several research firms have weighed in on RTTR. Maxim Group reissued a “buy” rating and issued a $5.00 price target on shares of Ritter Pharmaceuticals in a report on Monday, March 20th. Chardan Capital lowered their price target on shares of Ritter Pharmaceuticals from $4.50 to $3.50 and set a “buy” rating on the stock in a report on Thursday, March 30th. Finally, Zacks Investment Research raised shares of Ritter Pharmaceuticals from a “hold” rating to a “buy” rating and set a $0.75 price target on the stock in a report on Tuesday, May 23rd.

Ritter Pharmaceuticals (NASDAQ:RTTR) traded down 3.09% during midday trading on Monday, reaching $0.63. The company had a trading volume of 398,773 shares. The firm’s market capitalization is $9.21 million. The stock’s 50 day moving average price is $0.63 and its 200-day moving average price is $1.89. Ritter Pharmaceuticals has a one year low of $0.52 and a one year high of $3.75.

Ritter Pharmaceuticals (NASDAQ:RTTR) last released its quarterly earnings results on Tuesday, May 9th. The biotechnology company reported ($0.14) earnings per share for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.38) by $0.24. On average, equities research analysts anticipate that Ritter Pharmaceuticals will post ($1.30) earnings per share for the current year.

TRADEMARK VIOLATION WARNING: This piece of content was reported by American Banking News and is the property of of American Banking News. If you are accessing this piece of content on another domain, it was illegally stolen and republished in violation of U.S. & international copyright and trademark laws. The legal version of this piece of content can be accessed at https://www.americanbankingnews.com/2017/07/17/ritter-pharmaceuticals-inc-rttr-given-average-rating-of-buy-by-brokerages.html.

A hedge fund recently raised its stake in Ritter Pharmaceuticals stock. KCG Holdings Inc. raised its position in Ritter Pharmaceuticals, Inc. (NASDAQ:RTTR) by 259.0% during the first quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 105,409 shares of the biotechnology company’s stock after buying an additional 76,046 shares during the period. KCG Holdings Inc. owned approximately 0.91% of Ritter Pharmaceuticals worth $150,000 at the end of the most recent quarter. Institutional investors own 13.64% of the company’s stock.

About Ritter Pharmaceuticals

Ritter Pharmaceuticals, Inc develops therapeutic products that modulate the human gut microbiome to treat gastrointestinal diseases. The Company’s segment is focusing on the development and commercialization of RP-G28. The Company conducts human gut health research by exploring metabolic capacity of the gut microbiota and translating the functionality of prebiotic-based therapeutics into applications intended to have impact on a patient’s health.

Analyst Recommendations for Ritter Pharmaceuticals (NASDAQ:RTTR)

Receive News & Ratings for Ritter Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ritter Pharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.